2nd Fc Receptor & IgG Targeted Therapies Summit

FcRn, Fcγ, and IgG studies have been propelled by drug developers recently after Argenx’s potential FDA’s approval of first-in-class FcRn antagonist efgartigimod, AstraZeneca-Alexion’s $39 billion deal, and positive clinical updates from UCB’s Rozanolixizumab. Successful modulation of the Fc pathways and optimized IgG antibodies have proven clinical utility and demonstrate significant therapeutic potential with more players poised to bring their candidates through clinic.

The 2nd Fc Receptor & IgG Targeted Therapies Summit is the only dedicated meeting to bring you the most up-to-date with clinical and commercial developments on pioneering strategies to harness the full potential of FcRs.

This 3-day summit will return in 2022 with a fresh speaker line-up, 2 dedicated streams to offer you the A-Z of Fc receptors and IgG targeting. Bringing together exclusive data on targeting FcRn and FcyRs, and the engineering strategies employed to harness the FcR-IgG interaction to yield clinical efficacy. Hear from industry leaders such as FDA, Genentech, Alexion, UCB, Argenx, Genmab, and more as they modulate the dynamic behavior of IgG to fast-track candidates to address unmet medical needs.

Join 130+ experts in Boston to:
- Discuss translating novel Fc biology insights to innovative drug design
- Explore FcR antagonists, Fc fusion proteins, and novel antibodies
- Move confidently to clinic with predictive PKPD assessments from best-in-class cellular assays
- Enhance the therapeutic potential of antibodies with next-gen engineering strategies to minimize immunogenicity